What are the benefits of Dasatinib tablets?

The five main studies of dasatinib in adults involved 515 patients who were treated with imatinib and the treatment failed or stopped working. None of these studies compared dasatinib to another drug. Most of these studies assess leukemia's response to treatment by measuring the levels of white blood cells and platelets in the blood to see if they are returning to normal levels, and by measuring the number of white blood cells that contain the Philadelphia chromosome to see if it is declining. Two studies were conducted in patients with chronic myeloid leukemia (CML) (198 and 36 patients), one with accelerated CML (120 patients), one with myeloblastic CML (80 patients), and one with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and lymphoblastic CML (81 patients).

In a large major study of patients with chronic-phase CML, 90% had platelet and white blood cell levels return to within normal limits. Among patients with CML and ALL in other stages (accelerated, myeloblastic, and lymphoblastic), approximately 25-33% of patients have complete remission. Additionally, across five major studies, about 33% to 66% of treated patients had a reduced number of white blood cells containing the Philadelphia chromosome.

Two other studies compared dasatinib taken once or twice daily, one in 670 patients with chronic-phase CML and the other in 611 patients with late-stage CML or Ph+ ALL. Once- and twice-daily doses of dasatinib have similar effects, but the once-daily dose causes fewer side effects.

A further study involving 519 patients compared dasatinib and imatinib in the treatment of newly diagnosed chronic phase CML Ph+ patients who had not received any prior therapy. Dasatinib was more effective than imatinib, and within a year, 77% of patients who received dasatinib no longer had the Philadelphia chromosome in their blood cells, compared with 66% of patients who received imatinib.

Another major study looked at the efficacy of dasatinib in113 children with Ph+ chronic-phase CML, including 29 patients who were unable or refractory to imatinib and 84 newly diagnosed children who had not received prior treatment. Approximately 90% of patients who were unable to take imatinib or who were refractory to imatinib responded, and 94% of newly diagnosed patients responded.

On an item involvingA study of 106 children and adolescents with newly diagnosed Ph+ ALL who received dasatinib and chemotherapy. The primary measure of effectiveness is the proportion of patients who experience no adverse events during the 3-year treatment period. These events are: any sign of disease in the bone marrow, recurrence of disease anywhere in the body, a second cancer, or death. Among patients who received dasatinib and chemotherapy, 66% experienced no adverse events. This compares to 49% of patients who received chemotherapy alone and 59% of patients who received imatinib and chemotherapy, using previous study results.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).